Paper9028339
Altered erythrocytes and a leaky block in B-cell development in CD24/HSA-deficient mice.
Nielsen PJ and 9 others. Blood, 1997. Cited by 107 papers, by iCite.
Cite this record
ConductScience Library. Altered erythrocytes and a leaky block in B-cell development in CD24/HSA-deficient mice. Papers, record 9028339. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9028339
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, CD | Major topic |
| B-Lymphocytes | Major topic |
| Erythrocytes | Major topic |
| Hematopoiesis | Major topic |
| Membrane Glycoproteins | Major topic |
| Animals | |
| Bone Marrow | |
| Breeding | |
| CD24 Antigen | |
| Female | |
| Lymphocyte Count | |
| Malaria | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Inbred C57BL | |
| Mice, Knockout | |
| Plasmodium chabaudi | |
| Radiation Chimera | |
| T-Lymphocytes |
Source PubMed
Cited by69
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 107 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42792557 | Subcellular Localization of CD24 Is Associated with Integrin β1 Signaling, Immune Suppression, and Clinical Outcomes Across Human Cancers. | Biology (Basel) | 2026 | https://conductscience.org/library/papers/42792557 | PubMed |
| 41606146 | Mitoxantrone alters CD24/Siglec-10 expression in malignant brain tumor models. | Sci Rep | 2026 | https://conductscience.org/library/papers/41606146 | PubMed |
| 41186588 | Transcriptomics- and 3D imaging-based characterization of the lymphatic vasculature in human skin. | J Exp Med | 2026 | https://conductscience.org/library/papers/41186588 | PubMed |
| 40112946 | CD24 is required for sustained transparency of the adult lens. | Exp Eye Res | 2025 | https://conductscience.org/library/papers/40112946 | PubMed |
| 38962009 | Causal association between immune cells and lung cancer risk: a two-sample bidirectional Mendelian randomization analysis. | Front Immunol | 2024 | https://conductscience.org/library/papers/38962009 | PubMed |
| 38655691 | Contribution of VEGF-B-Induced Endocardial Endothelial Cell Lineage in Physiological Versus Pathological Cardiac Hypertrophy. | Circ Res | 2024 | https://conductscience.org/library/papers/38655691 | PubMed |
| 38279998 | Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions. | Cancer Immunol Immunother | 2024 | https://conductscience.org/library/papers/38279998 | PubMed |
| 37894750 | Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37894750 | PubMed |
| 37344099 | Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy. | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/37344099 | PubMed |
| 36969215 | Dendritic cell expression of CD24 contributes to optimal priming of T lymphocytes in lymph nodes. | Front Immunol | 2023 | https://conductscience.org/library/papers/36969215 | PubMed |
| 36948185 | Epigenetic dosage identifies two major and functionally distinct β cell subtypes. | Cell Metab | 2023 | https://conductscience.org/library/papers/36948185 | PubMed |
| 36425299 | CD24 as a Potential Therapeutic Target in Patients with B-Cell Leukemia and Lymphoma: Current Insights. | Onco Targets Ther | 2022 | https://conductscience.org/library/papers/36425299 | PubMed |
| 36138855 | Astrocytic CD24 Protects Neuron from Recombinant High-Mobility Group Box 1 Protein(rHMGB1)-Elicited Neuronal Injury. | Brain Sci | 2022 | https://conductscience.org/library/papers/36138855 | PubMed |
| 35921817 | CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder. | Cell Metab | 2022 | https://conductscience.org/library/papers/35921817 | PubMed |
| 35625912 | CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma. | Biomedicines | 2022 | https://conductscience.org/library/papers/35625912 | PubMed |
| 35559385 | CD24 is expressed on FoxP3+ regulatory T cells and regulates their function. | Am J Transl Res | 2022 | https://conductscience.org/library/papers/35559385 | PubMed |
| 33467499 | High Expression Level of PPARγ in CD24 Knockout Mice and Gender-Specific Metabolic Changes: A Model of Insulin-Sensitive Obesity. | J Pers Med | 2021 | https://conductscience.org/library/papers/33467499 | PubMed |
| 31246945 | Mouse HSA+ immature cardiomyocytes persist in the adult heart and expand after ischemic injury. | PLoS Biol | 2019 | https://conductscience.org/library/papers/31246945 | PubMed |
| 30231671 | CD24 is required for regulating gene expression, but not glucose uptake, during adipogenesis. | Adipocyte | 2018 | https://conductscience.org/library/papers/30231671 | PubMed |
| 29423273 | CD24-p53 axis suppresses diethylnitrosamine-induced hepatocellular carcinogenesis by sustaining intrahepatic macrophages. | Cell Discov | 2018 | https://conductscience.org/library/papers/29423273 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9028339
GET https://conductscience.org/api/papers/v1/9028339/cited_by?page=2